Rudra Prosad Goswami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rudra Prosad Goswami has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Alakendu Ghosh
Department of Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata
11 shared publications- Alakendu Ghosh
Department of Clinical Immunology and Rheumatology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
6 shared publications Parasar Ghosh
Department of Rheumatology, Institute of Post Graduate Medical Education and Research, Kolkata, India
6 shared publications- Uma Kumar
All India Institute of Medical Sciences
6 shared publications - Geetabali Sircar
Department of Rheumatology, Institute of Post Graduate Medical Education and Research, Kolkata, India
5 shared publications Moumita Chatterjee
Department of Mathematics and Statistics, Aliah University , Kolkata
5 shared publications
Latest Publications
- 15 August 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (11) , 1243-1252
Multitarget Therapy With Rituximab Plus Mycophenolate Mofetil Versus Rituximab Monotherapy in Systemic Sclerosis–Associated Interstitial Lung Disease
Objective: To compare the effectiveness and safety of rituximab (RTX) plus mycophenolate mofetil (MMF) vs RTX monotherapy in patients with systemic sclerosis–associated interstitial lung disease (SSc-ILD). Methods: We performed a retrospective comparative analysis among adults with radiologically confirmed SSc-ILD treated with RTX monotherapy or RTX plus MMF (a multitarget approach [MTT]) as an RTX-based treatment strategy. The primary outcome was improvement in percent predicted forced vital capacity (FVC%) > 5 percentage points at the end of the second year (ΔFVC > +5). Secondary outcomes included longitudinal FVC trajectories over 3 years, skin involvement, and safety. Longitudinal analyses used linear mixed-effects models, with additional sensitivity analyses using inverse probability of treatment weighting. Results: Among 109 patients (MTT, n = 42; RTX, n = 67), baseline FVC% was lower in the MTT group (50.6 vs 61.0). At the end of 2 years, ΔFVC > +5 occurred in 69% of patients receiving MTT compared with 33% receiving RTX alone. Over 3 years, the adjusted mean increase in FVC% was greater in the MTT group than in the monotherapy group (+12.9% vs +4.4%), with early separation of lung function trajectories that was sustained throughout follow-up. The association between MTT and greater FVC improvement remained consistent across prespecified subgroups, including patients with severe baseline restriction (FVC% < 45%). Herpes zoster occurred more frequently in the MTT group, whereas serious infections were uncommon in both groups. Conclusion: In this real-world study, RTX plus MMF was associated with favorable longitudinal FVC% trajectories compared with RTX monotherapy in a nonrandomized cohort, despite greater baseline disease severity in the MTT group. These findings support prospective evaluation of MTT, particularly in high-risk patients.
- 15 August 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (11) , 1243-1252
Multitarget Therapy With Rituximab Plus Mycophenolate Mofetil Versus Rituximab Monotherapy in Systemic Sclerosis–Associated Interstitial Lung Disease
Objective: To compare the effectiveness and safety of rituximab (RTX) plus mycophenolate mofetil (MMF) vs RTX monotherapy in patients with systemic sclerosis–associated interstitial lung disease (SSc-ILD). Methods: We performed a retrospective comparative analysis among adults with radiologically confirmed SSc-ILD treated with RTX monotherapy or RTX plus MMF (a multitarget approach [MTT]) as an RTX-based treatment strategy. The primary outcome was improvement in percent predicted forced vital capacity (FVC%) > 5 percentage points at the end of the second year (ΔFVC > +5). Secondary outcomes included longitudinal FVC trajectories over 3 years, skin involvement, and safety. Longitudinal analyses used linear mixed-effects models, with additional sensitivity analyses using inverse probability of treatment weighting. Results: Among 109 patients (MTT, n = 42; RTX, n = 67), baseline FVC% was lower in the MTT group (50.6 vs 61.0). At the end of 2 years, ΔFVC > +5 occurred in 69% of patients receiving MTT compared with 33% receiving RTX alone. Over 3 years, the adjusted mean increase in FVC% was greater in the MTT group than in the monotherapy group (+12.9% vs +4.4%), with early separation of lung function trajectories that was sustained throughout follow-up. The association between MTT and greater FVC improvement remained consistent across prespecified subgroups, including patients with severe baseline restriction (FVC% < 45%). Herpes zoster occurred more frequently in the MTT group, whereas serious infections were uncommon in both groups. Conclusion: In this real-world study, RTX plus MMF was associated with favorable longitudinal FVC% trajectories compared with RTX monotherapy in a nonrandomized cohort, despite greater baseline disease severity in the MTT group. These findings support prospective evaluation of MTT, particularly in high-risk patients.
- 25 June 2026
- Published by Wiley in Arthritis & Rheumatology
Clinical Images: Knot of Henry tenosynovitis mimicking enthesitis in spondyloarthritis
- 25 June 2026
- Published by Wiley in Arthritis & Rheumatology
Clinical Images: Knot of Henry tenosynovitis mimicking enthesitis in spondyloarthritis
- Open Access
- 23 April 2026
- Published by SAGE Publications in Indian Journal of Rheumatology
Normal Reproductive Outcomes in Women with Sjögren’s Disease Who Experience Pregnancies Before Disease Onset: A Multicentre Indian Cohort Study
Background: Sjögren’s disease (SS) is a chronic autoimmune disease with an estimated global prevalence of 6.9 per 100,000 person-years. However, population-based data from India are lacking. Information on reproductive health in Indian women with SS, particularly concerning marital status and pregnancy outcomes, is limited. Objective: To assess the impact of marital status on clinical and reproductive characteristics in women with SS and to compare pregnancy outcomes before and after disease onset among married women in India. Methods: This multicentre prospective observational study used data from the Indian Rheumatology Association (IRA) registry across seven centres. Female patients fulfilling the 2016 ACR/EULAR criteria for primary SS were included. Data on demographics, menstrual and reproductive history, and disease characteristics were collected using structured proformas. Reproductive health indicators were calculated using standard epidemiological methods. Results: Of 124 records, 115 female patients were included in the final analysis. The mean age at recruitment was 49.63 ± 10.31 years. The mean age at menarche was 13.74 ± 1.08 years, and 78.3% reported regular menstrual cycles. The mean age at disease onset was 41.34 ± 9.74 years, with a mean illness duration of 8.43 ± 5.4 years. Among married women ( n = 112), there were 236 pre-disease pregnancies resulting in 212 live births, with a CFR of 1.89. Pregnancy wastage ratio was 80.51 per 1,000 pregnancies, and stillbirth and abortion rates were 4.71 per 1,000 live births and 76.27 per 1,000 pregnancies, respectively. Vaginal delivery was the most common mode. Due to the very small number of unmarried participants ( n = 3) and those with pregnancy after disease onset ( n = 1), comparative analysis was not performed. Conclusion: Reproductive events in women with SS predominantly occurred before disease onset. Marital status was associated with age at diagnosis but not with adverse reproductive outcomes.
- 23 April 2026
- Published by SAGE Publications in Indian Journal of Rheumatology
Open AccessNormal Reproductive Outcomes in Women with Sjögren’s Disease Who Experience Pregnancies Before Disease Onset: A Multicentre Indian Cohort Study
Background: Sjögren’s disease (SS) is a chronic autoimmune disease with an estimated global prevalence of 6.9 per 100,000 person-years. However, population-based data from India are lacking. Information on reproductive health in Indian women with SS, particularly concerning marital status and pregnancy outcomes, is limited. Objective: To assess the impact of marital status on clinical and reproductive characteristics in women with SS and to compare pregnancy outcomes before and after disease onset among married women in India. Methods: This multicentre prospective observational study used data from the Indian Rheumatology Association (IRA) registry across seven centres. Female patients fulfilling the 2016 ACR/EULAR criteria for primary SS were included. Data on demographics, menstrual and reproductive history, and disease characteristics were collected using structured proformas. Reproductive health indicators were calculated using standard epidemiological methods. Results: Of 124 records, 115 female patients were included in the final analysis. The mean age at recruitment was 49.63 ± 10.31 years. The mean age at menarche was 13.74 ± 1.08 years, and 78.3% reported regular menstrual cycles. The mean age at disease onset was 41.34 ± 9.74 years, with a mean illness duration of 8.43 ± 5.4 years. Among married women ( n = 112), there were 236 pre-disease pregnancies resulting in 212 live births, with a CFR of 1.89. Pregnancy wastage ratio was 80.51 per 1,000 pregnancies, and stillbirth and abortion rates were 4.71 per 1,000 live births and 76.27 per 1,000 pregnancies, respectively. Vaginal delivery was the most common mode. Due to the very small number of unmarried participants ( n = 3) and those with pregnancy after disease onset ( n = 1), comparative analysis was not performed. Conclusion: Reproductive events in women with SS predominantly occurred before disease onset. Marital status was associated with age at diagnosis but not with adverse reproductive outcomes.
- Open Access
- 10 January 2026
- Published by Elsevier in Clinical Immunology Communications
- Vol. 9, 23-29
Disease-specific clustering is seen among first-degree relatives in autoimmune rheumatic diseases: A cross-sectional, multi-centre study
- 10 January 2026
- Published by Elsevier in Clinical Immunology Communications
- Vol. 9, 23-29
Open AccessDisease-specific clustering is seen among first-degree relatives in autoimmune rheumatic diseases: A cross-sectional, multi-centre study
- 10 October 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (10) , e70428
Discordance in Patient and Physician's Perception of Disease Activity Among Idiopathic Inflammatory Myopathy Patients: Insights From the COVAD Study
- 10 October 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (10) , e70428
Discordance in Patient and Physician's Perception of Disease Activity Among Idiopathic Inflammatory Myopathy Patients: Insights From the COVAD Study
- Open Access
- 13 July 2025
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 20 (4) , 352-361
Prevalence of Comorbidities Among Rheumatoid Arthritis Patients in India: A Multicentre Observational Study
Background: Comorbidities in rheumatoid arthritis (RA) patients vary significantly, with prevalence ranging from 3% to 60%. However, limited data exist from India. This study aims to evaluate the prevalence of comorbidities in RA patients in Indian clinical settings. Methods: The multicentre, observational study was conducted across eight centres in India using data from the Indian Rheumatology Association database. Comorbidities were classified using the International Classification of Diseases, Tenth revision (ICD-10) Charlson Comorbidity Index. Data were categorised by comorbidity, age and region and analysed using descriptive statistics, Fisher’s exact test, chi-squared test, t -test, analysis of variance (ANOVA) and logistic regression. Results: The study included 4,655 RA patients who met the European League Against Rheumatism (EULAR) classification criteria, with a mean age of 52.42 ± 12.18 years. Comorbidities were present in 41.72% of the patients. Those with comorbidities were older (56.16 vs. 49.74 years) and had a longer duration of RA (122.34 vs. 107.67 months). Out of 1,942 patients with comorbidities, 90% were female and 72% were from Southern India. The major comorbidities included hypertension (21.87%), thyroid disorders (14.5%) and diabetes (11.99%). Patients over 50 years had higher prevalence of diabetes, hypertension and cardiac diseases, while younger patients had more migraines and thyroid disorders. Conclusion: RA patients in India have a significantly higher burden of comorbidities, with hypertension, thyroid disorders and diabetes being the most common. Older age and a greater proportion of patients residing in Southern India were associated with increased comorbidities, suggesting potential regional differences in risk factors, healthcare access or lifestyle. These findings highlight the need for region- and age-specific management strategies.
- 13 July 2025
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 20 (4) , 352-361
Open AccessPrevalence of Comorbidities Among Rheumatoid Arthritis Patients in India: A Multicentre Observational Study
Background: Comorbidities in rheumatoid arthritis (RA) patients vary significantly, with prevalence ranging from 3% to 60%. However, limited data exist from India. This study aims to evaluate the prevalence of comorbidities in RA patients in Indian clinical settings. Methods: The multicentre, observational study was conducted across eight centres in India using data from the Indian Rheumatology Association database. Comorbidities were classified using the International Classification of Diseases, Tenth revision (ICD-10) Charlson Comorbidity Index. Data were categorised by comorbidity, age and region and analysed using descriptive statistics, Fisher’s exact test, chi-squared test, t -test, analysis of variance (ANOVA) and logistic regression. Results: The study included 4,655 RA patients who met the European League Against Rheumatism (EULAR) classification criteria, with a mean age of 52.42 ± 12.18 years. Comorbidities were present in 41.72% of the patients. Those with comorbidities were older (56.16 vs. 49.74 years) and had a longer duration of RA (122.34 vs. 107.67 months). Out of 1,942 patients with comorbidities, 90% were female and 72% were from Southern India. The major comorbidities included hypertension (21.87%), thyroid disorders (14.5%) and diabetes (11.99%). Patients over 50 years had higher prevalence of diabetes, hypertension and cardiac diseases, while younger patients had more migraines and thyroid disorders. Conclusion: RA patients in India have a significantly higher burden of comorbidities, with hypertension, thyroid disorders and diabetes being the most common. Older age and a greater proportion of patients residing in Southern India were associated with increased comorbidities, suggesting potential regional differences in risk factors, healthcare access or lifestyle. These findings highlight the need for region- and age-specific management strategies.
- 9 January 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (1) , 1-9
Increase in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study
Background: Psoriatic arthritis (PsA) significantly contributes to increased morbidity, reduced life expectancy, and higher healthcare costs due to the burden of comorbidities. This study assessed the prevalence of comorbidities in PsA patients in India and explored the influence of age and disease duration on these comorbidities. Methods: The prospective, multicenter observational study was conducted across seven centers in India, utilizing data from the Indian Rheumatology Association. Data were collected using expert-validated proformas, with comorbidities classified according to the ICD-10 Charlson Comorbidity Index. Participants were divided into two age groups: P < 0.001). The older group also had higher rates of hyperlipidemia (4.83% vs. 0.71%, P = 0.035) and hypertension (22.14%). Logistic regression revealed a significant association between age and the prevalence of diabetes, hypertension, and thyroid disorders (P = 0.003). Among patients over 40, 44.27% had at least one comorbidity. Conclusion: The study underscores the significant association between age and the prevalence of comorbidities in PsA patients, particularly in those over 40 years. These findings highlight the importance of targeted screening and management in older PsA patients.
- 9 January 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (1) , 1-9
Increase in comorbidities with age among patients with psoriatic arthritis: a multicenter observational study
Background: Psoriatic arthritis (PsA) significantly contributes to increased morbidity, reduced life expectancy, and higher healthcare costs due to the burden of comorbidities. This study assessed the prevalence of comorbidities in PsA patients in India and explored the influence of age and disease duration on these comorbidities. Methods: The prospective, multicenter observational study was conducted across seven centers in India, utilizing data from the Indian Rheumatology Association. Data were collected using expert-validated proformas, with comorbidities classified according to the ICD-10 Charlson Comorbidity Index. Participants were divided into two age groups: P < 0.001). The older group also had higher rates of hyperlipidemia (4.83% vs. 0.71%, P = 0.035) and hypertension (22.14%). Logistic regression revealed a significant association between age and the prevalence of diabetes, hypertension, and thyroid disorders (P = 0.003). Among patients over 40, 44.27% had at least one comorbidity. Conclusion: The study underscores the significant association between age and the prevalence of comorbidities in PsA patients, particularly in those over 40 years. These findings highlight the importance of targeted screening and management in older PsA patients.
- 18 November 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (11) , e15418
Defining Objective BASDAI Cut‐Offs for Disease Activity States and Improvement Scores in Axial Spondyloarthritis: A Multicentric Collaboration
Objective: To estimate objective cut‐off values for Bath ankylosing Spondylitis Disease Activity Index (BASDAI) corresponding to Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS) cut‐off values (1.3, 2.1, and 3.5), and for interval changes (ΔBASDAI) corresponding to ΔASDAS (1.1 and 2).Methods: In this multicentric study, adult patients with active axial spondyloarthritis (axSpA) treated with either tofacitinib 5 mg twice daily or adalimumab 40 mg subcutaneously fortnightly were recruited. Available paired data on BASDAI and ASDAS and paired interval change of these parameters (taken at least 3‐months apart) were analyzed. Cut‐off values for BASDAI were determined from a multinomial logistic regression and that for ΔBASDAI were determined with ordinal logistic regression with predicted probabilities. Diagnostics were assessed with correct classification rate (CRR), polychoric correlations (PCC), Goodman and Kruskal Gamma (GKG), and Matthew's correlation coefficient (MCC).Results: Total 962 observations of paired data and 670 interval change data were available from 266 patient (mean age 35 years, mean disease duration 7 years, mean BASDAI 2.7, and mean ASDAS 2.1). Following ASDAS classes were observed: inactive disease 131 (13.6%), moderate disease activity 322 (33.5%), high disease activity 420 (43.65%), and very high disease activity 89 (9.25%). The three cut‐offs generated for BASDAI were 0.8, 2.5, and 6 for BASDAI and those for ΔBASDAI were 2 and 4. The CRR for BASDAI cut‐offs was 65.59 and that for ΔBASDAI was 54.9. For the BASDAI cut‐offs, both PCC and GKG showed high values (> 0.85) and the MCC was 0.471.Conclusion: In patients with axSpA, without any clinical or serological confounders, BASDAI values 0.8, 2.5, and 6 corresponded to ASDAS‐CRP values 1.3, 2.1, and 3.5, respectively, and ΔBASDAI values of 2 and 4 correspond to ΔASDAS cut‐offs of 1.1 and 2.
- 18 November 2024
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (11) , e15418
Defining Objective BASDAI Cut‐Offs for Disease Activity States and Improvement Scores in Axial Spondyloarthritis: A Multicentric Collaboration
Objective: To estimate objective cut‐off values for Bath ankylosing Spondylitis Disease Activity Index (BASDAI) corresponding to Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS) cut‐off values (1.3, 2.1, and 3.5), and for interval changes (ΔBASDAI) corresponding to ΔASDAS (1.1 and 2).Methods: In this multicentric study, adult patients with active axial spondyloarthritis (axSpA) treated with either tofacitinib 5 mg twice daily or adalimumab 40 mg subcutaneously fortnightly were recruited. Available paired data on BASDAI and ASDAS and paired interval change of these parameters (taken at least 3‐months apart) were analyzed. Cut‐off values for BASDAI were determined from a multinomial logistic regression and that for ΔBASDAI were determined with ordinal logistic regression with predicted probabilities. Diagnostics were assessed with correct classification rate (CRR), polychoric correlations (PCC), Goodman and Kruskal Gamma (GKG), and Matthew's correlation coefficient (MCC).Results: Total 962 observations of paired data and 670 interval change data were available from 266 patient (mean age 35 years, mean disease duration 7 years, mean BASDAI 2.7, and mean ASDAS 2.1). Following ASDAS classes were observed: inactive disease 131 (13.6%), moderate disease activity 322 (33.5%), high disease activity 420 (43.65%), and very high disease activity 89 (9.25%). The three cut‐offs generated for BASDAI were 0.8, 2.5, and 6 for BASDAI and those for ΔBASDAI were 2 and 4. The CRR for BASDAI cut‐offs was 65.59 and that for ΔBASDAI was 54.9. For the BASDAI cut‐offs, both PCC and GKG showed high values (> 0.85) and the MCC was 0.471.Conclusion: In patients with axSpA, without any clinical or serological confounders, BASDAI values 0.8, 2.5, and 6 corresponded to ASDAS‐CRP values 1.3, 2.1, and 3.5, respectively, and ΔBASDAI values of 2 and 4 correspond to ΔASDAS cut‐offs of 1.1 and 2.
- 20 March 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (4) , e108-e114
Comparative Effectiveness of Tofacitinib and Adalimumab in Axial Spondyloarthritis
Introduction: Tofacitinib, an oral Janus kinase inhibitor, is a putative choice in the treatment of axial spondyloarthritis (AxSpA). The objective of this study was to compare the effectiveness and tolerability of tofacitinib with adalimumab, in AxSpA, in a real-world clinical setting. Methods: In this multicentric medical records review study, adult patients with active AxSpA treated with either tofacitinib 5 mg twice daily or adalimumab 40 mg subcutaneously fortnightly were recruited. Effectiveness was measured with Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Drug-cost analysis was calculated with Incremental Cost-Effectiveness Ratio (ICERdrug). Results: Among the 266 patients, 135 were treated with tofacitinib and 131 with adalimumab (follow-up: 6.5 ± 1.6 months). Mean improvement of BASDAI (3.39 ± 0.09 vs. 3.14 ± 1.16, respectively) and that of ASDAS (1.78 ± 0.68 vs. 2.07 ± 2.08, respectively) were comparable between the adalimumab and tofacitinib groups. A higher proportion of patients achieved BASDAI50 response in the second (49.5% vs. 31.6%) and fourth month (83.9% vs. 62.8%) and ASDAS low disease activity in the fourth month (71.6% vs. 47.9%) in the adalimumab group. All disease activity measurements were similar by the sixth month in both groups. A higher proportion of patients in the tofacitinib group than in the adalimumab group required change in therapy (14.8% vs. 7.6%, respectively). ICERdrug for adalimumab compared with tofacitinib was US $188.8 per patient in the adalimumab group for each person-month with BASDAI drug.
- 20 March 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (4) , e108-e114
Comparative Effectiveness of Tofacitinib and Adalimumab in Axial Spondyloarthritis
Introduction: Tofacitinib, an oral Janus kinase inhibitor, is a putative choice in the treatment of axial spondyloarthritis (AxSpA). The objective of this study was to compare the effectiveness and tolerability of tofacitinib with adalimumab, in AxSpA, in a real-world clinical setting. Methods: In this multicentric medical records review study, adult patients with active AxSpA treated with either tofacitinib 5 mg twice daily or adalimumab 40 mg subcutaneously fortnightly were recruited. Effectiveness was measured with Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Drug-cost analysis was calculated with Incremental Cost-Effectiveness Ratio (ICERdrug). Results: Among the 266 patients, 135 were treated with tofacitinib and 131 with adalimumab (follow-up: 6.5 ± 1.6 months). Mean improvement of BASDAI (3.39 ± 0.09 vs. 3.14 ± 1.16, respectively) and that of ASDAS (1.78 ± 0.68 vs. 2.07 ± 2.08, respectively) were comparable between the adalimumab and tofacitinib groups. A higher proportion of patients achieved BASDAI50 response in the second (49.5% vs. 31.6%) and fourth month (83.9% vs. 62.8%) and ASDAS low disease activity in the fourth month (71.6% vs. 47.9%) in the adalimumab group. All disease activity measurements were similar by the sixth month in both groups. A higher proportion of patients in the tofacitinib group than in the adalimumab group required change in therapy (14.8% vs. 7.6%, respectively). ICERdrug for adalimumab compared with tofacitinib was US $188.8 per patient in the adalimumab group for each person-month with BASDAI drug.
- 18 April 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (8) , 2155-2162
Mycophenolate mofetil as induction and maintenance immunosuppressive therapy in adult primary central nervous system vasculitis: A prospective observational study
To observe the clinical and angiographic effectiveness of mycophenolate mofetil (MMF) as induction and maintenance immunosuppressive therapy in primary central nervous system vasculitis (PCNSV). In this open-label prospective study done at a tertiary care neurology centre, adult patients with PCNSV, diagnosed by Calabrese’s criteria, were recruited from 2017 to 2021 and treated with glucocorticoids, MMF and standard of care. Patients were followed-up and clinical and angiographic changes were recorded. Total 26 patients were recruited with median age 39 years (34–49) with a slight female predilection (61.5%). Angiographic diagnoses were: small vessels disease 11.5%; large vessels disease 42.3% and both in 46.2%. Median duration of follow-up was 24.5 months (14.25–38). Proportion of patients with severe disability (modified Rankin Score (mRS) 4–6) at baseline was 73.08% (19/26) which reduced to 7.69% (2/26) (p < 0.001). At the last follow-up mRS = 0 was achieved in 38.5% (10/26) and mRS of ≤ 1 was achieved in 69.2% (18/26). Median time to achieve a mRS ≤ 1 was 12 months (95% CI: 6.8–17.2). Angiography was repeated in 16 patients after a median duration of 13 months (10.5–19.7), out of which 10 (62.5%) showed improvement and 5 (31.2%) showed non-progression of lesions. MMF may be an effective immunosuppressive therapy in adult PCNSV as both induction and maintenance. Serial DSA of brain may be useful to monitor the effect of treatment. Key Points • Mycophenolate mofetil is effective as induction and maintenance immunosuppressive therapy in PCNSV. • Repeat angiogram may be useful to monitor treatment response in PCNSV.
- 18 April 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (8) , 2155-2162
Mycophenolate mofetil as induction and maintenance immunosuppressive therapy in adult primary central nervous system vasculitis: A prospective observational study
To observe the clinical and angiographic effectiveness of mycophenolate mofetil (MMF) as induction and maintenance immunosuppressive therapy in primary central nervous system vasculitis (PCNSV). In this open-label prospective study done at a tertiary care neurology centre, adult patients with PCNSV, diagnosed by Calabrese’s criteria, were recruited from 2017 to 2021 and treated with glucocorticoids, MMF and standard of care. Patients were followed-up and clinical and angiographic changes were recorded. Total 26 patients were recruited with median age 39 years (34–49) with a slight female predilection (61.5%). Angiographic diagnoses were: small vessels disease 11.5%; large vessels disease 42.3% and both in 46.2%. Median duration of follow-up was 24.5 months (14.25–38). Proportion of patients with severe disability (modified Rankin Score (mRS) 4–6) at baseline was 73.08% (19/26) which reduced to 7.69% (2/26) (p < 0.001). At the last follow-up mRS = 0 was achieved in 38.5% (10/26) and mRS of ≤ 1 was achieved in 69.2% (18/26). Median time to achieve a mRS ≤ 1 was 12 months (95% CI: 6.8–17.2). Angiography was repeated in 16 patients after a median duration of 13 months (10.5–19.7), out of which 10 (62.5%) showed improvement and 5 (31.2%) showed non-progression of lesions. MMF may be an effective immunosuppressive therapy in adult PCNSV as both induction and maintenance. Serial DSA of brain may be useful to monitor the effect of treatment. Key Points • Mycophenolate mofetil is effective as induction and maintenance immunosuppressive therapy in PCNSV. • Repeat angiogram may be useful to monitor treatment response in PCNSV.